We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Patients with poorly controlled type 2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes, established cardiovascular ...

Results presented at the American Diabetes Association in June showed no CV risk or benefit and no risk of pancreatic injury, an issue that has been of particular concern to FDA. FDA has accepted a ...

Results first presented at the American Diabetes Association in June are published. The new drug application has since been filed at FDA. Results from the ELIXA trial, which showed that the GLP-1 ...

Lixisenatide (Lyxumia, sanofi-aventis) has been given a positive opinion for marketing in the European Union by the European Medicines Agency's Committee for Medicinal Products for Human Use. The ...

PARIS -- Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia® (lixisenatide) in adults with ...

PARIS, France, June 9, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data demonstrating Lyxumia®* (lixisenatide), a once-daily investigational GLP-1 agonist, in combination ...

(HealthDay News) — The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent ...

radiographic image of kidneys Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria. HealthDay News — For patients with type 2 diabetes and acute ...

Patients with early Parkinson disease who received lixisenatide had a decrease in motor disability progression, but they also experienced gastrointestinal side effects. Lixisenatide vs placebo is ...

BOSTON (updated June 9) — Lixisenatide (Lyxumia, Sanofi), an injectable glucagonlike peptide (GLP-1) agonist used for the treatment of type 2 diabetes, did not show a benefit on cardiovascular ...